3-iodobenzylguanidine has been researched along with cudc-907 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abid, K; Beck Popovic, M; Eugster, PJ; Fani, M; Gaonkar, RH; Grand-Guillaume, J; Grouzmann, E; Mansi, R; Zanger, S | 1 |
1 other study(ies) available for 3-iodobenzylguanidine and cudc-907
| Article | Year |
|---|---|
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Topics: 3-Iodobenzylguanidine; Animals; Histone Deacetylase Inhibitors; Humans; Mice; Neuroblastoma; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Precision Medicine | 2023 |